Thus far, only the EGFR-directed monoclonal antibody cetuximab has made it to the finish and is currently approved for the treatment of locoregionally advanced and recurrent/metastatic SCCHN, by the regulatory agencies of the United States and Europe. Here, EGFR is linked to head and neck squamous cell carcinoma.